Covidien To Host Investor Meeting On September 12, 2013

Covidien (NYSE: COV), a leading global provider of healthcare products, will host an investor meeting on Thursday, September 12, 2013, to update the investment community on the Company and its growth initiatives, strategic priorities and financial outlook. The event, held at Cipriani, 55 Wall Street, New York, NY, will begin at 10:00 a.m. ET and is expected to conclude by 5:00 p.m.

The program will include presentations by Covidien's Chairman, President and CEO José (Joe) Almeida and other members of the senior management team. A more detailed agenda will be communicated prior to the meeting.

Advanced registration is required and attendance will be limited to those who register in advance. To register for the meeting, please go to the following website: http://survey.covidien.com/f/537189/1e8a/.

Individuals who are unable to attend the meeting in person will be able to view a live video and webcast at Covidien’s website: http://investor.covidien.com. A replay of the presentations and the presentation materials will be available at the same website following the conclusion of the meeting.

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading products in medical devices and supplies. With 2012 revenue of $9.9 billion, Covidien has 38,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.

Copyright Business Wire 2010

If you liked this article you might like

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

Mallinckrodt Buys Ikaria in $2.3 Billion Hospital Treatment Deal

Stryker and Smith & Nephew Are the Stars to Watch in Medtech's 2015 Merger Dance

Medtronic Avoids U.S. Taxes While Saddling Shareholders With a Hefty Tax Bill

Trim Positions in Stryker Ahead of Fourth-Quarter Earnings; Buy on Pullback